Cargando…

m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent

PURPOSE: Immune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Jianqiu, Lu, Sihong, Zhang, Long, Yao, Yuhui, Zhang, Jie, Shen, Zefeng, Luo, Mingli, Liu, Bin, Zheng, Junjiong, Lin, Tianxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521425/ https://www.ncbi.nlm.nih.gov/pubmed/36189296 http://dx.doi.org/10.3389/fimmu.2022.1014861

Ejemplares similares

Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study
por: Zheng, Junjiong, et al.
Publicado: (2023)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
por: Liu, Yanhao, et al.
Publicado: (2022)

What role does PDL1 play in EMT changes in tumors and fibrosis?
por: Zhang, Yun-Chao, et al.
Publicado: (2023)

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
por: Jiang, Qi, et al.
Publicado: (2022)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study
por: Zhong, Weibo, et al.
Publicado: (2022)

Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Nomograms for the Prediction of Survival for Patients with Pediatric Adrenal Cancer after Surgery
por: Zheng, Junjiong, et al.
Publicado: (2020)

Depression and prostate cancer risk: A Mendelian randomization study
por: Chen, Xiong, et al.
Publicado: (2020)

Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021
por: Liu, Kun, et al.
Publicado: (2022)

Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder
por: Yang, Meihua, et al.
Publicado: (2022)

Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology
por: Fallon, Eleanor A., et al.
Publicado: (2021)

Programmed Cell Death Protein 1–PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection
por: Fonseca, Raíssa, et al.
Publicado: (2018)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis
por: Shen, Zefeng, et al.
Publicado: (2022)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
por: Sun, Zhuolun, et al.
Publicado: (2023)

Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the Absence of Tissue Restricted Antigens
por: Fergusson, Joannah R., et al.
Publicado: (2019)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance
por: Liu, Tiantian, et al.
Publicado: (2023)

PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8(+) T Cell Responses
por: Wang, Jun, et al.
Publicado: (2019)

A Model for Identifying Optimal Patients for Primary Tumor Resection in Patients With Metastatic Bladder Cancer
por: Hu, Jintao, et al.
Publicado: (2022)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial
por: Weed, Donald T., et al.
Publicado: (2019)

Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation
por: Germanidis, Georgios, et al.
Publicado: (2013)

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR
por: Purcell, James W., et al.
Publicado: (2014)

Synergistic Effects of Interferon-γ and Vitamin D(3) Signaling in Induction of ILT-3(high)PDL-1(high) Tolerogenic Dendritic Cells
por: Švajger, Urban, et al.
Publicado: (2019)

LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder
por: Pei, Lu, et al.
Publicado: (2023)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Outcome Predictors of Biopsy-Proven Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis
por: Ge, Yifei, et al.
Publicado: (2021)

Association of chromosome 7 aneuploidy measured by fluorescence in situ hybridization assay with muscular invasion in bladder cancer
por: Diao, Xiayao, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Study of B Cell Repertoire in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis
por: Feng, Jingjing, et al.
Publicado: (2020)

Global research trends and foci of artificial intelligence-based tumor pathology: a scientometric study
por: Shen, Zefeng, et al.
Publicado: (2022)

Whole-genome bisulfite sequencing reveals the function of DNA methylation in the allotransplantation immunity of pearl oysters
por: Gu, Zefeng, et al.
Publicado: (2023)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_phlta6q6v7h23kh4mi3qfq1rar